Crown Holdings Inc Stock News

Beyond analysts' top -and-bottom-line estimates for Crown (CCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter en

Crown (CCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

TAMPA, Fla. , April 2, 2024 /PRNewswire/ -- Crown Holdings, Inc. (NYSE:CCK) will release its earnings for the first quarter ended March 31, 2024 after the close of trading on the New York Stock Excha

Revenue fell as materials cost savings are passed on to customers. Today, investors were disappointed by guidance for flat earnings in 2024.

Crown Holdings' (CCK) fourth-quarter top line reflects the impacts of lower volumes across most businesses, offset by higher beverage can unit volumes in Americas Beverage.

The headline numbers for Crown (CCK) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimate

Crown Holdings (CCK) came out with quarterly earnings of $1.24 per share, missing the Zacks Consensus Estimate of $1.42 per share. This compares to earnings of $1.17 per share a year ago.

Evaluate the expected performance of Crown (CCK) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics fo

Crown (CCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TAMPA, Fla. , Jan. 8, 2024 /PRNewswire/ -- Crown Holdings, Inc. (NYSE:CCK) will release its earnings for the fourth quarter ended December 31, 2023 after the close of trading on the New York Stock Ex

Crown (CCK) reported earnings 30 days ago. What's next for the stock?

CCK demonstrates steady growth and reinvestment patterns. Shares are valued inexpensively at 9x EBITDA and 14x earnings. At current levels, the buyback is accretive for shareholders.

That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.

Activist investor Carl Icahn has lowered his holdings in beverage-can maker Crown Holdings CCK about a year after he bought a stake in the company.